HEIP
UTHR icon

Hudson Edge Investment Partners’s United Therapeutics UTHR Stock Holding History

Hudson Edge Investment Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-252
Closed -$57.9K – 201
2024
Q1 		$57.9K Buy
+252
New +$56.9K 0.01% 159
2015
Q2 		– Sell
-1,821
Closed -$314K – 154
2015
Q1 		$314K Sell
1,821
-1,717
-49% -$262K 0.01% 132
2014
Q4 		$458K Sell
3,538
-805
-19% -$104K 0.02% 124
2014
Q3 		$559K Buy
4,343
+928
+27% +$95.7K 0.02% 111
2014
Q2 		$302K Buy
3,415
+700
+26% +$67.3K 0.01% 130
2014
Q1 		$255K Sell
2,715
-110
-4% -$11.3K 0.01% 132
2013
Q4 		$319K Sell
2,825
-180
-6% -$16.2K 0.01% 125
2013
Q3 		$237K Buy
+3,005
New +$220K 0.01% 137

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hudson Edge Investment Partners's UTHR Position: Q2 2024 in Review

Hudson Edge Investment Partners sold out of United Therapeutics (UTHR) in Q2 2024, closing a stake of 252 shares — an estimated $57.9K sold.

Hudson Edge Investment Partners first reported a position in UTHR in Q3 2013 and held it in 8 quarters. The position peaked at $559K in Q3 2014. 566 funds tracked by Wall St. Rank hold UTHR as of Q2 2024.

  • Hudson Edge Investment Partners reported no remaining United Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Hudson Edge Investment Partners sold 252 United Therapeutics shares in Q2 2024, an estimated $57.9K.
  • Hudson Edge Investment Partners first reported a position in United Therapeutics in Q3 2013 and held it in 8 quarters.
  • Hudson Edge Investment Partners's United Therapeutics position peaked at $559K in Q3 2014.
  • 566 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2024.

Based on Hudson Edge Investment Partners's 13F filing for Q2 2024, filed 6 Aug 2024.